RetaCalc
Protocol library
SingleInvestigationalEarly HumanLow confidenceSourced

ACE-031

An activin receptor fusion protein studied in early human trials. Development in Duchenne muscular dystrophy stopped after vascular safety concerns.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Vial-aware arithmetic

No reconstitution example shown

The human schedules are weight-based and no matched research-vial strength or reconstitution method was recovered, so a fixed vial-to-U-100 example would require invented formulation assumptions.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Human StudySubcutaneousSingle exposure
Healthy postmenopausal women

A single subcutaneous dose across 0.02 mg/kg to 3 mg/kg cohorts

This ascending-dose study assessed short-term safety, pharmacokinetics and body composition.

View source
Human StudySubcutaneousEvery 2 or 4 weeks
Ambulatory boys with Duchenne muscular dystrophy

0.5 mg/kg subcutaneously every 4 weeks or 1 mg/kg every 2 weeks for 12 weeks

The controlled study stopped early because of potential safety concerns and did not establish routine use.

View source
Evidence GapNot reported in archiveNot reported in archive
authenticated research-forum (Peppys) archive check

No reproducible ACE-031 dose, route, reconstitution or cycle was found; a deep capture of the archive returned zero threads and zero attached protocol documents

The forum search surfaced ACE-031 only in mechanism-only index entries (myostatin-pathway inhibition, muscle growth) with no quantities. No community schedule exists, so the page stays anchored to the early human studies rather than manufacturing one.

View source

Evidence summary

An activin receptor fusion protein studied in early human trials. Development in Duchenne muscular dystrophy stopped after vascular safety concerns.

Protocol basis

The protocol page is anchored to two early clinical programmes and foregrounds why a study interval should not be interpreted as a continuing-use plan.

What remains uncertain

A favourable benefit-risk profile, authorised indication, long-term safety and commercial product equivalence are not established.

Online research community archive check

No ACE-031 occurrence was found in the reviewed raw online research community archive. The page therefore remains anchored to the early human studies rather than inventing a community schedule.

Community provenance (Peppys)

A deep capture of the authenticated research forum (Peppys) returned no ACE-031 threads and no attached protocol documents. Earlier index entries mention ACE-031 only by mechanism, as a myostatin-pathway molecule linked to muscle growth, without any dose, route, reconstitution or cycle. Because no reproducible community protocol exists, this page keeps its evidence-gap framing and stays anchored to the early human trials rather than manufacturing a forum schedule.

Warnings and contraindications

ACE-031 clinical development was stopped after epistaxis and telangiectasia concerns.
It is a fusion protein rather than a short peptide.
Early changes in body composition did not establish an authorised therapeutic protocol.